There are currently 112 clinical trials in Fullerton, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Retina Consultants of Orange County, Neurology Center of North Orange County, Saint Jude Medical Center and Providence Medical Foundation. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
NCT05354141
Recruiting
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/21/2024
Locations: Direct Biologics Investigational Site, Fullerton, California
Conditions: Acute Respiratory Distress Syndrome, ARDS
Register for Updates
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171
Recruiting
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Providence Medical Foundation, Fullerton, California
Conditions: Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Register for Updates
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
NCT05948826
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Providence Medical Foundation, Fullerton, California
Conditions: Advanced Solid Tumor, Colorectal Cancer
Register for Updates
MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms
NCT05285553
Recruiting
The purpose of this post-approval study is to confirm the effectiveness of the MiSight 1 Day lens in clinical practices within the US and to assess the stability of the myopia reduction over one-year post-treatment.
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
10/17/2024
Locations: Marshall B. Ketchum University Southern California College of Optometry, Fullerton, California
Conditions: Myopia
Register for Updates
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636
Recruiting
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies ha... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
10/14/2024
Locations: Retina Consultants of Orange County, Fullerton, California
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Register for Updates
Molecular Genetics Studies of Cancer Patients and Their Relatives
NCT04185935
Recruiting
This trial studies the genetic and behavioral factors that may contribute to the development of specific cancers and how these factors may affect the outcome of the disease in patients with a history of cancer and their relatives.
Gender:
ALL
Ages:
All
Trial Updated:
10/01/2024
Locations: Saint Jude Medical Center, Fullerton, California
Conditions: Malignant Neoplasm
Register for Updates
Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT04553770
Recruiting
This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: St. Joseph Heritage Healthcare, Fullerton, California
Conditions: Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
Register for Updates
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
NCT06061809
Recruiting
This is a phase 2 open-label study to evaluate the safety and efficacy of N-803 and PD-L1 t-haNK when combined with Bevacizumab in subjects with recurrent or progressive GBM. Participants will receive N-803 subcutaneously (SC), PD-L1 t-haNK intravenously (IV), and Bevacizumab IV combination therapy. Treatment for all enrolled participants will consist of repeated cycles of 28 days for a maximum treatment period of 76 weeks (19 cycles). Treatment will be administered on days 1 and day 15 of eac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2024
Locations: Providence Medical Foundation, Fullerton, California
Conditions: Glioblastoma
Register for Updates
Beacon Sensors and Telerehabilitation to Assess and Improve Use of Devices (BeST-AID) for Low Vision
NCT06107881
Recruiting
One goal of this research is to conduct a non-inferiority trial of telerehabilitation versus in-office care to provide follow-up training to individuals with low vision to enhance their quality of life by using magnification devices and/or visual assistive mobile apps for important daily activities, such as reading and/or other valued tasks. This is a high priority given the increasing prevalence of low vision, paucity of low vision rehabilitation providers, and barriers related to access to car... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Southern Califonia College of Optometry, Fullerton, California
Conditions: Low Vision, Low Vision Aids
Register for Updates
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
NCT05271292
Recruiting
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2024
Locations: Providence/St. Joe Cancer Institute/Crosson Cancer Institute, Fullerton, California
Conditions: Advanced Solid Malignant Tumor, Small Cell Lung Cancer
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Saint Jude Medical Center, Fullerton, California
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
NCT05230537
Recruiting
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/24/2024
Locations: Retina Consultants of Orange County, Fullerton, California
Conditions: Age-Related Macular Degeneration
Register for Updates